195 related articles for article (PubMed ID: 9658393)
1. Antisense therapy of hepatitis B virus infection.
Offensperger WB; Offensperger S; Blum HE
Mol Biotechnol; 1998 Apr; 9(2):161-70. PubMed ID: 9658393
[TBL] [Abstract][Full Text] [Related]
2. Therapy of hepadnavirus infection using antisense oligonucleotides.
Offensperger WB; Blum HE; Gerok W
Intervirology; 1995; 38(1-2):113-9. PubMed ID: 8666519
[TBL] [Abstract][Full Text] [Related]
3. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.
Yang L; Shi LP; Chen HJ; Tong XK; Wang GF; Zhang YM; Wang WL; Feng CL; He PL; Zhu FH; Hao YH; Wang BJ; Yang DL; Tang W; Nan FJ; Zuo JP
Acta Pharmacol Sin; 2014 Mar; 35(3):410-8. PubMed ID: 24487969
[TBL] [Abstract][Full Text] [Related]
4. [Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B].
Chen XM; Liu ZM; Du XF; Yang ZG; Chen XM
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 34(2):121-5. PubMed ID: 15812884
[TBL] [Abstract][Full Text] [Related]
5. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.
Le Guerhier F; Thermet A; Guerret S; Chevallier M; Jamard C; Gibbs CS; Trépo C; Cova L; Zoulim F
J Hepatol; 2003 Mar; 38(3):328-34. PubMed ID: 12586299
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activities of penciclovir and famciclovir on duck hepatitis B virus in vitro and in vivo.
Offensperger WB; Offensperger S; Keppler-Hafkemeyer A; Hafkemeyer P; Blum HE
Antivir Ther; 1996 Aug; 1(3):141-6. PubMed ID: 11322247
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.
Hafkemeyer P; Keppler-Hafkemeyer A; al Haya MA; von Janta-Lipinski M; Matthes E; Lehmann C; Offensperger WB; Offensperger S; Gerok W; Blum HE
Antimicrob Agents Chemother; 1996 Mar; 40(3):792-4. PubMed ID: 8851615
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitory effect of trisodium phosphonoformate (PFA) on duck hepatitis B virus (DHBV) DNA in vivo].
Chen X; Chen H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):277-81. PubMed ID: 15617348
[TBL] [Abstract][Full Text] [Related]
9. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.
Zoulim F; Dannaoui E; Borel C; Hantz O; Lin TS; Liu SH; Trépo C; Cheng YC
Antimicrob Agents Chemother; 1996 Feb; 40(2):448-53. PubMed ID: 8834896
[TBL] [Abstract][Full Text] [Related]
10. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
Seignères B; Martin P; Werle B; Schorr O; Jamard C; Rimsky L; Trépo C; Zoulim F
Antimicrob Agents Chemother; 2003 Jun; 47(6):1842-52. PubMed ID: 12760857
[TBL] [Abstract][Full Text] [Related]
11. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
Nicoll A; Locarnini S; Chou ST; Smallwood R; Angus P
J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
[TBL] [Abstract][Full Text] [Related]
12. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus.
Mason WS; Cullen J; Saputelli J; Wu TT; Liu C; London WT; Lustbader E; Schaffer P; O'Connell AP; Fourel I
Hepatology; 1994 Feb; 19(2):398-411. PubMed ID: 8294097
[TBL] [Abstract][Full Text] [Related]
14. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
15. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro.
Wang GF; Shi LP; Ren YD; Liu QF; Liu HF; Zhang RJ; Li Z; Zhu FH; He PL; Tang W; Tao PZ; Li C; Zhao WM; Zuo JP
Antiviral Res; 2009 Aug; 83(2):186-90. PubMed ID: 19463857
[TBL] [Abstract][Full Text] [Related]
16. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.
Offensperger WB; Offensperger S; Walter E; Teubner K; Igloi G; Blum HE; Gerok W
EMBO J; 1993 Mar; 12(3):1257-62. PubMed ID: 8458338
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
[TBL] [Abstract][Full Text] [Related]
18. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.
Fourel I; Cullen JM; Saputelli J; Aldrich CE; Schaffer P; Averett DR; Pugh J; Mason WS
J Virol; 1994 Dec; 68(12):8321-30. PubMed ID: 7966625
[TBL] [Abstract][Full Text] [Related]
19. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
20. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo.
Noordeen F; Vaillant A; Jilbert AR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5299-306. PubMed ID: 23939904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]